| 09/11/2026 9:30 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/10/2026 9:31 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/10/2026 7:53 AM | GLAXOSMITHKLINE CAPITAL INC (1224462) Filer GSK (1131399) Filer | Form 424B2 Transaction specifc information for a delayed shelf offering | |
| 09/10/2026 5:09 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/09/2026 9:45 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/09/2026 9:31 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/09/2026 5:19 AM | GSK (1131399) Subject | Form FWP | |
| 09/08/2026 8:06 AM | GLAXOSMITHKLINE CAPITAL INC (1224462) Filer GSK (1131399) Filer | Form 424B2 Transaction specifc information for a delayed shelf offering | |
| 09/08/2026 7:27 AM | GLAXOSMITHKLINE CAPITAL INC (1224462) Filer GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 11:26 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/01/2026 6:46 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Shocking AI prediction from the “Billionaire Whisperer" (Ad) Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percent run, and Nvidia before it climbed more than 50,000 percent.
Now Chaikin says a new AI data center technology using 99 percent less electricity, water, and space could accelerate scientific breakthroughs 360-fold, and one company behind it just flashed bullish in his system.
See the full research and the ticker Chaikin is watching before this presentation goes offline. Watch Chaikin's free presentation and see the ticker now |
| 08/26/2026 9:37 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/24/2026 9:35 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/24/2026 5:57 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/24/2026 5:20 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/20/2026 10:19 AM | GSK (1131399) Subject Martinez Maria E (1761768) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/18/2026 9:34 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/13/2026 3:32 PM | GSK (1131399) Filer | Form 13F-HR Initial Quarterly Form 13F Holdings report filed by institutional managers | |
| 08/13/2026 10:33 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/11/2026 10:03 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/03/2026 10:16 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/30/2026 11:25 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/22/2026 11:52 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/20/2026 9:13 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/17/2026 6:14 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/17/2026 5:50 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/16/2026 9:45 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/15/2026 8:11 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/15/2026 8:00 AM | GSK (1131399) Filed by Nuvalent, Inc. (1861560) Subject | Form SC TO-T/A | |
| 07/14/2026 10:20 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/13/2026 10:28 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/13/2026 5:29 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/10/2026 7:44 AM | GSK (1131399) Filed by Nuvalent, Inc. (1861560) Subject | Form SC TO-T/A | |
| 07/10/2026 7:13 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/09/2026 10:27 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/09/2026 6:27 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/07/2026 3:44 PM | GSK (1131399) Filed by Nuvalent, Inc. (1861560) Subject | Form SC TO-T/A | |
| 07/01/2026 9:02 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/29/2026 9:25 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/29/2026 9:20 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/26/2026 9:02 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
The income “unicorn” Todd Phillips has been waiting 2 years to see again (Ad) Retirement income specialist Todd Phillips once tracked an unusual income vehicle nicknamed the 10.3 percent Unicorn. It vanished from the market within 12 to 18 months, with no warning.
Now a similar structure has resurfaced, one Todd calls the 10.3 percent War Bond, built for investors who want dependable income without tracking the stock market daily. Todd says the current rate ranks among the highest hes seen in 30 years. Click here to see the 10.3 percent War Bond Blueprint now |
| 06/24/2026 3:03 PM | GSK (1131399) Filed by Nuvalent, Inc. (1861560) Subject | Form SC TO-T/A | |
| 06/24/2026 9:39 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/24/2026 9:46 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/24/2026 6:15 AM | GSK (1131399) Filed by Nuvalent, Inc. (1861560) Subject | Form SC TO-T | |
| 06/23/2026 10:05 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/22/2026 10:00 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/17/2026 11:20 AM | GSK (1131399) Filer | Form 11-K Annual reports of employee stock purchase, savings and similar plans pursuant to Section 15(d) | |
| 06/17/2026 11:02 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/17/2026 11:04 AM | GSK (1131399) Filer | Form 11-K Annual reports of employee stock purchase, savings and similar plans pursuant to Section 15(d) | |
| 06/15/2026 9:02 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/12/2026 5:32 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/11/2026 9:42 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/10/2026 3:54 PM | GSK (1131399) Filed by Nuvalent, Inc. (1861560) Subject | Form SC TO-C | |
| 06/10/2026 9:36 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/09/2026 4:20 PM | GSK (1131399) Filed by Nuvalent, Inc. (1861560) Subject | Form SC TO-C | |
| 06/09/2026 12:37 PM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/09/2026 6:13 AM | GSK (1131399) Filed by Nuvalent, Inc. (1861560) Subject | Form SC TO-C | |
| 06/09/2026 5:18 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/01/2026 9:46 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/01/2026 9:00 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/28/2026 5:02 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/27/2026 9:34 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/26/2026 9:23 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/26/2026 9:17 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/22/2026 6:19 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/20/2026 9:39 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/20/2026 9:40 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/19/2026 10:01 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/18/2026 10:03 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/18/2026 5:29 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/14/2026 3:45 PM | GSK (1131399) Filer | Form 13F-HR Initial Quarterly Form 13F Holdings report filed by institutional managers | |
| 05/14/2026 11:22 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/11/2026 9:59 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/11/2026 5:42 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/11/2026 5:31 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/06/2026 12:52 PM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/06/2026 10:18 AM | FMR LLC (315066) Filed by GSK (1131399) Subject | Form SCHEDULE 13G | |
| 05/05/2026 11:54 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/01/2026 10:08 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/01/2026 10:11 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/29/2026 11:00 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/29/2026 7:09 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/28/2026 10:18 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/28/2026 6:24 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/27/2026 7:13 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/27/2026 5:58 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/24/2026 10:20 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/23/2026 5:03 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/22/2026 5:06 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/21/2026 5:03 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Gold led me to Mount Rushmore (Ad) A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technology. This could be one of the biggest gold finds since the 1870s, yet the stock still trades around 6 dollars.
BlackRock and Vanguard have been quietly loading up on shares while most investors have missed the story. The same technology is unlocking hidden resource wealth across America, driving stocks up 227 percent, 378 percent, and even 773 percent. Watch the free video and get the stock name now |
| 04/20/2026 11:46 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/20/2026 5:37 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/20/2026 5:19 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/17/2026 5:16 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/16/2026 12:01 PM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/16/2026 5:42 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/15/2026 5:39 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/15/2026 5:05 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/14/2026 10:22 AM | GSK (1131399) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |